LENZ Therapeutics, Inc. $LENZ Shares Acquired by Skandinaviska Enskilda Banken AB publ

Skandinaviska Enskilda Banken AB publ lifted its stake in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) by 99.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 185,642 shares of the company’s stock after purchasing an additional 92,362 shares during the quarter. Skandinaviska Enskilda Banken AB publ owned about 0.65% of LENZ Therapeutics worth $8,647,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of the stock. Sovran Advisors LLC lifted its position in LENZ Therapeutics by 164.5% in the third quarter. Sovran Advisors LLC now owns 106,920 shares of the company’s stock valued at $4,980,000 after purchasing an additional 66,497 shares during the period. Saturn V Capital Management LP acquired a new position in LENZ Therapeutics during the 2nd quarter worth approximately $10,033,000. Stempoint Capital LP purchased a new position in shares of LENZ Therapeutics during the 2nd quarter worth approximately $5,390,000. Geode Capital Management LLC lifted its holdings in shares of LENZ Therapeutics by 15.5% in the 2nd quarter. Geode Capital Management LLC now owns 416,122 shares of the company’s stock valued at $12,198,000 after buying an additional 55,730 shares during the period. Finally, Candriam S.C.A. acquired a new stake in shares of LENZ Therapeutics in the 2nd quarter valued at approximately $5,020,000. 54.32% of the stock is owned by institutional investors and hedge funds.

LENZ Therapeutics Trading Down 2.1%

NASDAQ:LENZ opened at $12.77 on Thursday. The company has a market capitalization of $399.57 million, a P/E ratio of -6.05 and a beta of 0.50. The firm has a 50-day moving average price of $16.64 and a two-hundred day moving average price of $28.86. LENZ Therapeutics, Inc. has a twelve month low of $12.48 and a twelve month high of $50.40.

Wall Street Analyst Weigh In

LENZ has been the subject of several research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of LENZ Therapeutics in a research report on Thursday, January 22nd. HC Wainwright reaffirmed a “buy” rating on shares of LENZ Therapeutics in a research note on Monday, December 15th. Finally, Zacks Research cut shares of LENZ Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 20th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $56.40.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.